Introduction {#Sec1}
============

^18^F-fluorodeoxyglucose positron emission tomography/computed tomography (FDG-PET/CT) is an effective and popular technique for evaluating patients before and after breast cancer surgery. This is because a single scan allows visualization of lymph node metastasis and common sites of breast cancer metastasis, such as the lungs, liver, and bone \[[@CR1]--[@CR4]\] and even small lesions anywhere in the body.

Quantitative FDG-PET/CT imaging is becoming prevalent in cancer treatment as it measures glucose metabolism that reflects the growth potential and metabolic activity of malignant tumors. These data cannot be obtained by morphological diagnosis using CT or magnetic resonance imaging (MRI). The FDG-PET/CT findings of primary lesions in colorectal and lung cancers correlate with metastasis and prognosis because FDG reflects tumor viability \[[@CR5]--[@CR7]\]. The technique is valuable for predicting the prognosis of patients with recurrent breast cancer and for determining and predicting the outcomes of neoadjuvant chemotherapy \[[@CR8]--[@CR10]\]. Therefore, FDG-PET/CT is useful not only for evaluating metastasis but also for predicting the prognosis of recurrent breast cancer and measuring treatment effects. However, reports remain limited to small-scale clinical trials of about 100 patients.

If the maximum standardized uptake value (maxSUV) became a prognostic factor for breast cancer, then the selection of general preoperative chemotherapy, endocrine, targeted, and localized therapies such as surgery and radiation might help to improve patient prognoses and quality of life. The present study examines the relationship between maxSUV, degree of malignancy of the primary lesion, and prognosis in two medical facilities that used different PET/CT devices.

Patients and methods {#Sec2}
====================

This study enrolled 344 patients with stages I--III breast cancer who underwent preoperative FDG-PET/CT and radical surgery at the Hiroshima University Department of Surgical Oncology and the Shikoku Cancer Center between January 2006 and December 2011. Patients who had undergone neoadjuvant therapy were excluded. The Institutional Review Board of each facility approved the study, and results from the database were analyzed in a retrospective multi-facility collaboration.

FDG-PET/CT imaging {#Sec3}
------------------

The patients fasted for at least 4 h before being intravenously injected with 3.7 MBq/kg of FDG, and then rested for 1--1.5 h before being evaluated. Blood glucose was measured before tracer injection to ensure a level of 150 mg/dL. Patients with blood glucose values of \>150 mg/dL during PET/CT image acquisition were excluded. All patients were assessed using an integrated Discovery ST16 PET/CT (GE Healthcare, Little Chalfont, UK) or an Aquiduo (Toshiba Medical Systems Corporation, Otawara, Japan) scanner. Unenhanced CT images of 2--4-mm thick sections that matched the PET images were acquired from the head to the pelvic floor of each patient using a standard protocol. Immediately after CT, PET covered the identical axial FOV during 2--4 min per table position depending on the condition of the patient and the scanner performance. Both PET and CT studies proceeded with the patient under normal tidal breathing. All PET images were reconstructed using an iterative algorithm with CT-derived attenuation correction using Fourier re-binning followed by ordered-subset expectation maximization (iteration number 5, subset number 16). MaxSUV was established by drawing regions of interest (ROI) around the primary tumor on attenuation-corrected FDG-PET images and calculated using the software integrated within the PET/CT scanner based on the formula:$$\documentclass[12pt]{minimal}
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Histological examination {#Sec4}
------------------------

Nuclear grade was determined according to General Rules for Clinical and Pathological Recording of Breast Cancer, 17th edition \[[@CR11]\]. The presence of estrogen (ER) and progesterone (PgR) receptors was assessed by immunohistochemistry (IHC) and scored according to the Allred system. Human epidermal growth factor receptor-2 (HER-2) positivity was defined as 3+ by IHC or 2+ by gene amplification using fluorescence in situ hybridization (FISH) of \>2.2-fold.

Statistical analysis {#Sec5}
--------------------

Data are presented as numbers (%) or as mean ± SD unless otherwise stated. Frequencies were compared in all patients using the Chi-square test for categorical variables. Continuous variables were analyzed using a *t* test. Recurrence was analyzed using a multivariable analysis with the Cox proportional hazards regression model. Recurrence-free survival (RFS) was defined as elapsed time from the date of surgery until the first event (relapse or death from any cause) or last follow-up. The duration of RFS was analyzed using the Kaplan--Meier method. Differences in RFS were assessed using the log rank test. Data were analyzed using the Statistical Package for the Social Sciences v. 10.5 (SPSS Inc., Chicago, IL, USA).

Results {#Sec6}
=======

MaxSUV, which is the most popular FDG-PET/CT value, can vary up to 30 % because of differences among PET/CT devices and among the operators who create the images \[[@CR12]\]. Consequently, adjustments are necessary to determine whether maxSUV is an accurate and objective indicator in multi-facility collaborative studies involving different PET/CT devices. Therefore, we used a phantom to initially adjust for differences in maxSUV values determined at the two facilities (Fig. [1](#Fig1){ref-type="fig"}). The maxSUV values of the two facilities are indicated by black and white squares, respectively, and the original maxSUV values (left panel) were compared with the revised values (right panel), which were adjusted to approximately equalize the maxSUV values at both facilities.Fig. 1MaxSUV adjusted using experimental phantom

Table [1](#Tab1){ref-type="table"} shows the features of the study participants. Mean maxSUV values were determined for patients grouped according to age, clinical stage (such as T- and N-factors; Table [1](#Tab1){ref-type="table"}), pathological factors (nuclear grade, ER, HER-2, and vascular invasion), and the presence or absence of recurrence (Table [2](#Tab2){ref-type="table"}). The mean age of the study participants was 58.0 ± 12.5 years. The maxSUV increased with increased staging levels or degrees of malignancy, such as N-factor, nuclear grade, and vascular invasion, and maxSUV was associated with biochemical factors such as ER and HER-2 levels.Table 1Patients' characteristics*n*Rate (%)MaxSUV (mean ± SD)Clinical T-factor T124170.12.76 ± 2.00 T210129.45.83 ± 4.12 T320.64.86 ± 1.31Clinical N-factor N026175.93.47 ± 3.03 N16719.53.95 ± 2.76 N2123.55.48 ± 4.49 N341.26.57 ± 5.21Clinical stage  I19456.42.61 ± 1.82  II134394.96 ± 3.71  III164.75.76 ± 4.70*SD* standard deviationTable 2Pathological findings*n*Rate (%)MaxSUV (mean ± SD)Nuclear grade 179232.94 ± 1.99 212235.53.27 ± 3.12 314341.64.43 ± 3.46ER (+)29284.93.43 ± 2.77 (−)5215.15.01 ± 4.40PgR (+)25674.43.33 ± 2.67 (−)8825.64.68 ± 4.00HER2 (+)4713.75.01 ± 3.56 (−)29786.33.46 ± 2.99LNM (+)110324.02 ± 2.92 (−)234683.51 ± 3.20VI (+)9427.33.87 ± 2.77 (−)25072.73.60 ± 3.24*ER* estrogen receptor, *HER2* human epidermal factor receptor 2, *LNM* lymph node metastasis, *PgR* progesterone receptor *VI* vascular invasion

The relationship between maxSUV and breast cancer recurrence was investigated. The revised maxSUV was used to create receiver operating characteristic (ROC) curves for recurrence (area under the curve = 0.713) in which the cut-off maxSUV was 3.0 (Fig. [2](#Fig2){ref-type="fig"}). The patients were assigned to one of two groups according to the cut-off (Fig. [2](#Fig2){ref-type="fig"}), and then relationships between clinicopathological factors and maxSUV were examined (Table [3](#Tab3){ref-type="table"}). Univariate analysis revealed correlations between maxSUV and the presence or absence of recurrence, clinical T-factor, HER-2, nuclear grade, clinical N-factor, PgR, and ER ranked in ascending order based on odds ratios.Fig. 2Receiver operating characteristics (ROC) curves of maxSUV for recurrence in all patients (*n* = 344). Optimal cut-off of maxSUV, 3.0 (*n* = 344, AUC: 0.713; 95 % CI 0.612--0.814, *p* = 0.003)Table 3Comparison of clinicopathological parameters between maxSUV ≤ 3.0 and \>3.0VariablesMaxSUV ≤ 3.0 (*n* = 199)MaxSUV \> 3.0 (*n* = 145)Odds ratio (95 % CI)*p*Age58.9 ± 12.356.7 ± 12.70.1165Clinical T-factor T1169725.71\<0.0001 T2, T33073(3.44--9.48)Clinical N-factor N0162992.030.0049 N1, N2, N33746(1.23--3.35)Nuclear grade 1, 2134672.4\<0.0001 36578(1.54--3.73)ER (+)1761161.910.0309 (−)2329(1.06--3.47)PgR (+)159971.970.0063 (−)4048(1.21--3.21)HER-2 (+)1821152.790.0012 (+)1730(1.47--5.29)LNM (−)146881.780.0128 (+)5357(1.13--2.82)VI (−)155951.850.011 (+)4450(1.15--2.99)Recurrence (−)1961316.980.0014 (+)314(1.97--24.77)

Figure [3](#Fig3){ref-type="fig"} shows Kaplan--Meier RFS curves for maxSUV, clinical T- and N-factors, nuclear grade, ER and HER-2 that are known prognostic factors for breast cancer. Recurrence-free survival significantly correlated with clinical T-factor and ER, and the log-rank test showed that maxSUV also significantly correlated with recurrence (*p* = 0.001) (Fig. [3](#Fig3){ref-type="fig"}a). However, N-factor, nuclear grade, or HER-2 did not correlate.Fig. 3Recurrence-free survival (RFS) curves of patients according to predictive factors. 5-year RFS rates for patients with **a** maxSUV ≤ 3.0 and \>3.0, **b** clinical T-factor T1 and T2, 3, **c** clinical N-factors N0 and N1, 2, 3, **d** nuclear grades 1, 2, and 3 **e** ER (+) and ER (−) and **f** HER2 (−) and HER2 (+)

Univariate analysis of recurrence in all patients included the variables of age, clinical T- and N-factors, maxSUV, nuclear grade, ER, and HER-2. Both maxSUV and ER were significant prognostic factors (Table [4](#Tab4){ref-type="table"}, *p* = 0.004 and *p* \< 0.001, respectively) and clinical T-factor and HER-2 were potentially associated with recurrence (*p* \< 0.1). Multivariate analysis selected both maxSUV and ER as independent prognostic factors (Table [4](#Tab4){ref-type="table"}, *p* = 0.033 and *p* = 0.004, respectively).Table 4Univariate and multivariate analysis of recurrence using Cox modelFactorsFavorableUnfavorableHazard ratio (95 % CI)*p*Univariate analysis Age (year)\<58≥581.086 (0.419--2.818)0.865 Clinical T-factorT1T2, T32.579 (0.994--6.692)0.051 Clinical N-factorN0N1,N2,N31.683 (0.622--4.550)0.305 MaxSUV≤3.0\>3.06.177 (1.773--21.519)0.004 Nuclear grade1, 232.076 (0.790--5.458)0.138 ER(+)(−)5.528 (2.132--14.336)\<0.001 HER2(−)(+)2.661 (0.937--7.554)0.066Multivariate analysis Age\<58≥581.338 (0.496--3.607)0.565 Clinical T-factorT1T2, T31.668 (0.597--4.656)0.329 Clinical N-factorN0N1, N2, N31.183 (0.418--3.344)0.751 MaxSUV≤3.0\>3.04.350 (1.127--16.786)0.033 Nuclear grade1, 230.955 (0.332--2.745)0.932 ER(+)(−)4.624 (1.635--13.082)0.004 HER2(−)(+)1.247 (0.407--3.824)0.699

Discussion {#Sec7}
==========

The prognostic factors applied in breast cancer can be broadly divided into those that determine staging and those that determine biological tumor characteristics. Factors that determine the rate of cancer progression include T-factor (tumor diameter) and N-factor (presence or absence/number of lymph node metastasis). Factors that determine the nature of tumors also include ER, HER-2, Ki-67 labeling index, and nuclear grade. Prognosis was previously predicted based on T, N, and M staging, which indicates the degree of progression. However, prognosis is now predicted and treatment regimes are presently selected by also considering ER and HER-2 levels, which determine the nature of the tumor \[[@CR13]--[@CR15]\]. Increasing the number of prognostic factors should result in more accurate and improved patient prognoses through the selection of more individualized therapies.

Although conventional CT or MRI can provide information for morphological diagnoses, FDG-PET/CT adds further information, such as that regarding tumor growth potential. In particular, maxSUV presently serves as an indicator of metabolic activity during cancer therapy. For instance, the maxSUV of primary lung and hematological cancer lesions correlates with metastasis and prognosis, whereas maxSUV also seems useful for predicting the prognosis of recurrent breast cancer and in determining and predicting the outcome of neoadjuvant chemotherapy \[[@CR7], [@CR16]\]. However, these reports are mainly derived only from small-scale single-facility studies, and data about sample sizes are insufficient to draw conclusions.

The retrospective clinical analysis at two medical facilities included 344 patients with stages I--III operable breast cancer. Chemotherapy and hormone therapy were administered at each facility, according to guidelines for case staging and biological characteristics \[[@CR17], [@CR18]\]. Patients who had received neoadjuvant chemotherapy were excluded to simplify the analysis, and 84.9, 13.7, and 10.2 % of the patients had ER-positive, HER-2-positive, and triple-negative breast cancers, respectively. ER receptor-positive breast cancers were relatively common, whereas the odds ratios for HER-2-positive breast cancers and triple-negative breast cancers were quite low.

The maxSUV cut-off calculated from ROC curves for recurrence was 3.0, and when the patients were divided based on this cut-off, maxSUV significantly correlated with almost all clinicopathological factors for breast cancer. Because of the large number of clinicopathological factors for breast cancer such as tumor diameter, lymph node metastasis ER, and HER-2, we assumed that maxSUV would be the ultimate output of these factors. For example, the degree of malignancy would increase with an increase in maxSUV when ER or HER-2 signaling is involved.

Univariate and multivariate analyses identified both ER status and maxSUV as independent prognostic factors. Furthermore, since clinical T- and N-factors, nuclear grade, and HER-2 were not included as prognostic factors in our analyses, we can state that maxSUV has a closer correlation with prognosis than these factors. Moreover, RFS was assessed using Kaplan--Meier curves and the log-rank test, which revealed that maxSUV, clinical T-factor and ER were significant prognostic factors, as noted above. Statistical analysis of RFS and multivariate analysis demonstrated that maxSUV was a useful novel prognostic factor for breast cancer in our patients.

Our results showed that maxSUV has the potential to be a novel prognostic factor and that it can be used to determine future therapies. However, different courses of treatment are currently prescribed for each biological characteristic (subtype). Thus, the distribution and characteristics of the maxSUV must be known before courses of treatment can be determined. The maxSUV was the highest for the triple-negative type among all of the subtypes \[[@CR19]\]. In the future, steps are needed to determine the cut-offs for each subtype in more patients including those with luminal, HER-2 and triple-negative breast cancers, to determine courses of treatment.

Our results indicate that maxSUV could serve as a new prognostic factor for breast cancer, but more data should be accumulated from more patients. Moreover, maxSUV might be used as a factor to predict the effects of chemotherapy and endocrine therapy.
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